

Merchant & Gould

An Intellectual Property Law Firm

10 East Doty Street
Suite 600
Madison, Wisconsin
53703 USA
TEL 608.280.6750
FAX 612.332.9081
www.merchantgould.com

A Professional Corporation

Direct Contact

Jeffrey S. Ward
jward@merchantgould.com
608-280-6751

SENT BY FEDERAL EXPRESS

January 20, 2015

J. Michael Pearson, CEO
Bausch & Lomb Incorporated
1400 North Goodman Street
Rochester, NY 14609

Yukoh Yoshida, President & CEO
Senju Pharmaceutical Co., Ltd.
2-5-8, Hirano-machi, Chuo-ku
Osaka, Japan

Re: Paragraph IV certification, notice letter, and offer of confidential access for Bromfenac Sodium Ophthalmic Solution/Drops EQ 0.07% Acid, Paddock Laboratories, LLC ANDA No. 207584.

Dear Sir:

I am writing to inform you that Paddock Laboratories, LLC ("Paddock") has submitted an abbreviated new drug application to the United States Food and Drug Administration (FDA) containing one or more "paragraph IV" certifications in order to obtain approval to engage in the commercial manufacture, use, or sale of bromfenac sodium ophthalmic solution/drops, EQ 0.07% acid ("the Paddock product").

Paddock's abbreviated new drug application ("Paddock's ANDA" or "the application") was submitted pursuant to 21 U.S.C. § 355(j) and received by the FDA. Paddock's ANDA contains any required bioavailability or bioequivalence data or information.

Paddock's ANDA has been assigned No. 207584.

The established name of the drug product is bromfenac sodium ophthalmic solution/drops. The active ingredient, strength, and dosage forms of the proposed drug product are: bromfenac sodium EQ 0.07% acid, ophthalmic solution/drops.

Atlanta

Denver

Knoxville

Madison

Minneapolis

New York

Seattle

Washington DC

DOCKET
ALARM

Find authenticated court documents without watermarks at docketalarm.com.

Bausch & Lomb
Senju Pharmaceutical Co., Ltd.
January 20, 2015
Page 2

The application included a certification under § 355(j)(2)(A)(vii)(IV) for United States Patent No. 8,927,606 (“the ‘606 patent”). Paddock has certified that in its opinion and to the best of its knowledge, the claims of the ‘606 patent will not be infringed by Paddock’s proposed manufacture, use, or sale of its product that is the subject of its application, and/or those claims are invalid or unenforceable. According to Bausch and Lomb’s entry in the FDA’s electronic Orange Book, the ‘606 patent expires on January 16, 2024.

As required by 21 U.S.C. § 355(j)(2)(B)(ii), a detailed statement of the factual and legal bases for Paddock’s opinion is set forth below. Furthermore, this enclosure also contains an offer of confidential access pursuant to 21 U.S.C. § 355(j)(5)(C)(iii).

Pursuant to 21 C.F.R. § 314.95(e), Paddock requested and received from the FDA permission to send this notice to the NDA holder and patent owner by means other than registered or certified mail. The FDA granted Paddock’s request prior to this notice being sent.

The name and address of an agent authorized to accept service of process for Paddock is:

Shane A. Brunner, Edward J. Pardon, Jeffrey S. Ward, or Wendy M. Ward
Merchant & Gould PC
10 E. Doty Street, Suite 600
Madison, WI 53703-3376

DETAILED STATEMENT

I. Legal Standards

General legal standards utilized here are discussed below. More detailed law is discussed in the analysis sections as needed.

A. Claim Construction

The first step in an infringement or invalidity analysis is to construe the claims. Claim construction is an issue of law, performed by the court, even in a jury trial. *Markman v. Westview Instruments, Inc.*, 52 F.3d 967, 979 (Fed. Cir. 1995), *aff’d*, 517 U.S. 370 (1996). The interpretation to be given a claim is formed by the claim language itself, the language of the other claims in the patent, the specification of the patent, the prior art, and the prosecution history. *SRI Int’l v. Matsushita Elec. Corp.*, 775 F.2d 1107, 1118 (Fed. Cir. 1985). Claim terms are

generally given their ordinary and established meanings to one of ordinary skill in the art. *Phillips v. AWH Corp.*, 415 F.3d 1303, 1312-13 (Fed. Cir. 2005).

The specification is the primary basis for construing the claims, because that is where the inventor provides a full and exact description of the invention. *Phillips*, 415 F.3d at 1315-17. The claims themselves, both asserted and unasserted, are also a valuable source with respect to claim construction. *Id.* at 1314. The prosecution history should also be consulted. *Id.* at 1317. Review of the prosecution history can reveal whether there are any express limitations made regarding the scope and meaning of the claims. *Bell Atlantic Network Servs., Inc. v. Covad Commc'ns Group, Inc.*, 262 F.3d 1258, 1268 (Fed. Cir. 2001). In addition, extrinsic evidence such as dictionaries, technical treatises, articles that are publicly available at the time the patent issued, and expert testimony may also be considered, but this evidence is less significant than the patent itself and its prosecution history. *Phillips*, 415 F.3d at 1317-19.

B. Infringement

After the claim is interpreted, it must be compared to the accused device or process to determine whether the claim's scope encompasses the accused device or process. *North Am. Vaccine, Inc. v. American Cyanamid Co.*, 7 F.3d 1571, 1574 (Fed. Cir. 1993). If the properly interpreted terms of the claim read on the accused device or process, literal infringement is established. *Morton Int'l, Inc. v. Cardinal Chem. Co.*, 5 F.3d 1464, 1468 (Fed. Cir. 1993). Because each element of a claim is material and essential, the patent owner must show the presence of each and every element in the accused device to establish literal infringement. *Charles Greiner & Co. v. Mari-Med Mfg., Inc.*, 962 F.2d 1031, 1034 (Fed. Cir. 1992). The patentee has the burden to show infringement by a preponderance of the evidence. *SmithKline Diagnostics, Inc. v. Helena Laboratories Corp.*, 859 F. 2d 878, 889 (Fed. Cir. 1988).

Absent literal infringement, a legal doctrine termed the doctrine of equivalents may apply to bring an accused device or process under the web of infringement. *Hughes Aircraft Co. v. United States*, 717 F.2d 1351, 1361 (Fed. Cir. 1983). Under the doctrine of equivalents, a patent owner may be successful in an infringement action, even if the claims are not literally infringed, if "the accused product or process contain[s] elements identical or equivalent to each claimed element of the patented invention." *Warner-Jenkinson Co. v. Hilton Davis Chem. Co.*, 520 U.S. 17, 40 (1997). In applying the doctrine of equivalents, one considers if the differences between the claimed structure or process and the accused device or process are insubstantial from the vantage point of one of ordinary skill in the relevant art. *Hilton Davis Chem. Co. v. Warner-Jenkinson Co.*, 62 F.3d 1512,

1517-18 (Fed. Cir. 1995), *rev'd on other grounds and remanded*, 520 U.S. 17 (1997). It is often enough to assess whether the accused device or process performs substantially the same function in substantially the same way to obtain substantially the same result as the claim element(s) missing from the accused structure or process under the literal infringement analysis. *Hilton Davis*, 62 F.3d at 1518. Furthermore, a patent owner must show the presence of every element or its substantial equivalent in the accused device or process to prove infringement under the doctrine of equivalents. *Pennwalt Corp. v. Durand-Wayland, Inc.*, 833 F.2d 931, 935 (Fed. Cir. 1987).

Application of the doctrine of equivalents can be precluded in certain situations as a matter of law. For example, a patent owner cannot obtain, under the doctrine of equivalents, coverage that could not lawfully have been obtained from the USPTO by literal claims. *Pennwalt*, 833 F.2d at 938. In other words, a claim cannot be read to cover an accused device under the doctrine of equivalents if that claim would then be unpatentable in view of prior art. *Wilson Sporting Goods Co. v. David Geoffrey and Assocs.*, 904 F.2d 677, 684 (Fed. Cir. 1990). In addition, a patentee is precluded from capturing subject matter under the doctrine of equivalents that was disclosed in the patent specification but not claimed by the patentee. *Johnson & Johnston Assocs., Inc. v. R.E. Serv. Co.*, 285 F.3d 1046 (Fed. Cir. 2002) (en banc). Furthermore, a patentee cannot assert the doctrine of equivalents where to do so would "vitiate" or completely read a limitation out of a claim. *Warner-Jenkinson Co.*, 520 U.S. at 39 n.8; *DePuy Spine, Inc. v. Medtronic Sofamor Danek, Inc.*, 469 F.3d 1005, 1017 (Fed. Cir. 2006).

Where an accused activity does not include particular limitations of an independent claim or their substantial equivalents, it follows that, for the same reason, the dependent claims will not be infringed. *Jeneric/Pentron, Inc. v. Dillon Co.*, 205 F.3d 1377, 1383 (Fed. Cir. 2000) ("dependent claims cannot be found infringed unless the claims from which they depend have been found to have been infringed") (citation omitted).

C. Obviousness

A claimed invention in an issued patent is invalid if it would have been obvious to one of ordinary skill in the art at the time the invention was made when viewed in light of the prior art. 35 U.S.C. § 103. Obviousness is a question of law, based on underlying fact issues. *Graham v. John Deere Co.*, 383 U.S. 1, 17-18 (1966). These fact issues are: (1) the scope and content of the prior art; (2) the differences between the claimed invention and the prior art; (3) the level of ordinary skill in the art; and (4) secondary considerations, including unexpected

results and commercial success. *KSR Int'l Co. v. Teleflex, Inc.*, 550 U.S. 398, 406 (2007).

To prove obviousness based on a combination of references, it can be helpful to identify whether there must be some reason to combine those references. *KSR*, 550 U.S. at 418-19. The reason to combine references can be provided by any need or problem that is known in the field of endeavor at the time of the invention and addressed by the patent at issue. *Id.* at 420. In addition, where there is a need to solve a problem, and there are a finite number of identified, predictable solutions, a person of ordinary skill in the art has good reason to pursue those solutions. If this leads to anticipated success, it is likely the product of ordinary skill and common sense, and is not inventive. *Id.* at 421.

II. Description of the '606 Patent

A. Background

The '606 patent is entitled "Aqueous Liquid Preparation Containing 2-Amino-3(4-Bromobenzoyl)Phenylacetic Acid." The patent issued on January 6, 2015 from U.S. application No. 14/ 493,903("the '903 application"). The '903 application was a divisional of U.S. Application No. 14/261,720 ("the '720 application"), now U.S. Patent No. 8,871,813, which was filed on April 25, 2014 as a divisional of the U.S. Application No. 14/165,976 ("the '976 application"), now the U.S. Patent No. 8,754,131. The '976 application was filed on January 28, 2014, as a divisional of U.S. Application No. 13/687,242 ("the '242 application"), now U.S. Patent No. 8,669,290. The '242 application was filed on November 28, 2012 as a divisional of U.S. Application No. 13/353,653 ("the '653 application"), now U.S. Patent No. 8,497,304. The '653 application was filed on January 19, 2012 as a divisional of the U.S. Application No. 10/525,006 ("the '006 application"), which became U.S. Patent No. 8,129,431. The '006 application was the U.S. national phase of PCT application PCT/JP2004/000350, filed on January 16, 2004. The PCT application claimed priority to a Japanese patent application filed on January 21, 2003. The '606 patent lists Shirou Sawa and Shuhei Fujita as inventors. It is assigned to Senju Pharmaceutical Co., Ltd. ("Senju"). The '813 patent expires January 16, 2024, according to the entry in the Orange Book.

B. Claims

The '606 patent contains thirty claims, three of which are independent: claims 1, 11 and 19. These claims are reproduced below.

1. A method for treating an inflammatory disease of an eye, the method comprising administering to said eye a stable aqueous liquid preparation that comprises: (a) a first

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.